| Project/Area Number |
15K09226
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Wakayama Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
洪 泰浩 和歌山県立医科大学, 医学部, 准教授 (80426519)
赤松 弘朗 和歌山県立医科大学, 医学部, 助教 (10646582)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
KIKUCHI Takashi 和歌山県立医科大学, 医学部, 助教 (40649050)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | がん個別化医療 / 肺がん / リキッドバイオプシー / EGFR変異 / デジタルPCR / 分子標的治療 / EGFR / 新規診断技術 / 肺癌 |
|---|
| Outline of Final Research Achievements |
We developed a multiplex digital PCR assay to detect 3 common EGFR mutations (L858R, exon 19 deletion T790M) in 1 reaction. Liquid biopsy (LB) has been approved to detect epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC). However, the clinical significance of monitoring the disease using LB remains elusive.
We conducted a clinical study evaluating the significance of serial tracking of EGFR mutation using plasma DNA. Chemotherapy naive, advanced NSCLC patients with EGFR-sensitizing mutation received afatinib until progressive disease (PD) or unacceptable toxicity. Fifty-seven patients were registered in the study. After treatment, negative conversion of sensitizing mutation within four weeks was observed among 87.5% of the patients. These patients demonstrated significantly longer progression-free survival than those without negative conversion. LB is a useful method to predict durable efficacy in EGFR mutated NSCLC patients.
|
